Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy

Br J Clin Pharmacol

1 May 2020 - The reimbursement of the immune checkpoint inhibitors is challenging. 

Funding these technologies involves the careful balance between awarding innovation and ensuring affordability as increases in drug spending compete directly with other health care and social expenditure. 

This narrative review examined the recommendations of two HTA agencies: Australian Pharmaceutical Benefits Advisory Committee (PBAC) and the British National Institute of Clinical Excellence (NICE) to determine the factors that contribute to the approval and rejection of ICIs as well as the use of manage entry schemes and risk management strategies to control expenditure.

Read British Journal of Clinical Pharmacology article

Michael Wonder

Posted by:

Michael Wonder